Slide 1: Pfizer Provides Full-Year 2024 Financial Guidance
Pfizer Provides Full-Year 2024 Financial Guidance December 13, 2023 Breakthroughs that change patients' lives ®
Slide 2: Introduction
Introduction Francesca DeMartino Chief Investor Relations Officer, Senior Vice President
Slide 3: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Our discussions during this conference call will include forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such sta
Slide 4: Opening Remarks
Opening Remarks Albert Bourla Chairman and Chief Executive Officer
Slide 5: Seagen Acquisition: Strategic Rationale
Seagen Acquisition: Strategic Rationale • 1 in 3 people will be diagnosed with cancer in their lifetime; it is the 2nd leading cause of death in the U.S.1 and a leading cause of death worldwide2 • Combining the oncology expertise of both companies, together with Seagen’s pioneering antibody-drug con
Slide 6: Pfizer and Seagen: Stronger Combined
Pfizer and Seagen: Stronger Combined R&D Advancement Portfolio Expansion Commercial Enhancement • Pfizer and Seagen will further develop • The deal is expected to enhance Pfizer’s • Combined U.S. infrastructure will be 3 ADCs, which are poised to replace topline growth immediately, driven by times t
Slide 7: The New Pfizer Oncology Division
The New Pfizer Oncology Division Chris Boshoff Legacy Pfizer Colleague Chief Oncology Officer Legacy Seagen Colleague Kamran Roger Sriram Megan Guy Adam Jeff Karin Suneet Ansari Dansey Krishnaswami O’Meara Padbury Schayowitz Settleman Tollefson Varma Head, Clinical Chief Head, Scientific Head, Early
Slide 8: Additional Organizational Updates
Additional Organizational Updates Aamir Malik Alexandre de Germay Chief U.S. Chief International Commercial Officer, EVP Commercial Officer, EVP • Angela Hwang will be leaving Pfizer after a stellar nearly 27-year career at Pfizer • Leaders will begin transitioning to their new roles immediately aft
Slide 9: Financial Review
Financial Review David Denton Chief Financial Officer, Executive Vice President
Slide 10: 2024 Financial Guidance
2024 Financial Guidance1 2024 Legacy Royalty 2024 Seagen 2024 Financial 2023 Guidance2 Pfizer Guidance1 Reclass3 Impact Guidance1 Reported Revenues $58.0 – $61.0B4 $54.5 – $57.5B4 ~$1.0B* ~$3.1B $58.5 – $61.5B Adjusted1 SI&A Expenses $13.3 – $14.3B $13.8 – $14.8B Adjusted1 R&D Expenses $11.9 – $12.9
Slide 11: Key Takeaways
Key Takeaways • 2024 Guidance Assumes: o Including Seagen, Op Revenue Growth (ex-Comirnaty and Paxlovid) of 8-10%1 o Op Revenue Growth (ex-Comirnaty and Paxlovid & ex-Seagen) of 3-5%1 o Comirnaty & Paxlovid Revenues of ~$8B (Comirnaty ~$5B; Paxlovid ~$3B) • Cost realignment program now expected to a
Slide 12: Q&A Session
Q&A Session
Slide 13: Analyst Meeting
Analyst Meeting Oncology R&D Day February 29in NYC 13
Slide 14: Footnotes
Footnotes (1) Pfizer does not provide guidance for GAAP Reported financial measures (other than revenues and in 2023 acquired in-process R&D [IPR&D] expenses) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP Reported financial measures on a forw